Sandbox/diarrhea: Difference between revisions

Jump to navigation Jump to search
No edit summary
m (Bot: Automated text replacement (-Category:Primary care +))
 
(12 intermediate revisions by 2 users not shown)
Line 2: Line 2:
{{CMG}}; {{M.P}}
{{CMG}}; {{M.P}}


==Antibiotic Therapy==
===Pathogen Specific===
==Pathogen Specific==
<SMALL><font color="#FF4C4C"> '''▸ Click on the following categories to expand treatment regimens.'''<ref name="pmid11170940">{{cite journal| author=Guerrant RL, Van Gilder T, Steiner TS, Thielman NM, Slutsker L, Tauxe RV et al.| title=Practice guidelines for the management of infectious diarrhea. | journal=Clin Infect Dis | year= 2001 | volume= 32 | issue= 3 | pages= 331-51 | pmid=11170940 | doi=10.1086/318514 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11170940  }} </ref><ref name="pmid20307191">{{cite journal| author=Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC et al.| title=Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). | journal=Infect Control Hosp Epidemiol | year= 2010 | volume= 31 | issue= 5 | pages= 431-55 | pmid=20307191 | doi=10.1086/651706 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20307191  }} </ref></font></SMALL>
<SMALL><font color="#FF4C4C"> '''▸ Click on the following categories to expand treatment regimens.'''<ref name="pmid11170940">{{cite journal| author=Guerrant RL, Van Gilder T, Steiner TS, Thielman NM, Slutsker L, Tauxe RV et al.| title=Practice guidelines for the management of infectious diarrhea. | journal=Clin Infect Dis | year= 2001 | volume= 32 | issue= 3 | pages= 331-51 | pmid=11170940 | doi=10.1086/318514 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11170940  }} </ref><ref name="pmid20307191">{{cite journal| author=Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC et al.| title=Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). | journal=Infect Control Hosp Epidemiol | year= 2010 | volume= 31 | issue= 5 | pages= 431-55 | pmid=20307191 | doi=10.1086/651706 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20307191  }} </ref></font></SMALL>


Line 227: Line 226:
<div style="border-radius: 0 0 0 0; border: solid 1px #20538D; border-bottom: 0px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #A1BCDD; text-align: center;">
<div style="border-radius: 0 0 0 0; border: solid 1px #20538D; border-bottom: 0px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #A1BCDD; text-align: center;">
<font color="#FFF">
<font color="#FFF">
'''Parasites'''
'''Giardia species'''
</font>
</font>
</div>
</div>


<div class="mw-customtoggle-table42" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
<div class="mw-customtoggle-table88" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
<font color="#FFF">
<font color="#FFF">
&nbsp;&nbsp;▸&nbsp;&nbsp;'''Giardia'''
&nbsp;&nbsp;▸&nbsp;&nbsp;'''Adults'''
</font>
</div>
 
<div class="mw-customtoggle-table89" style="cursor: pointer; border-radius: 0 0 5px 5px; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
<font color="#FFF">
&nbsp;&nbsp;▸&nbsp;&nbsp;'''Children'''
</font>
</div>
 
<div style="border-radius: 0 0 0 0; border: solid 1px #20538D; border-bottom: 0px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #A1BCDD; text-align: center;">
<font color="#FFF">
'''Cryptosporidium species'''
</font>
</div>
 
<div class="mw-customtoggle-table70" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
<font color="#FFF">
&nbsp;&nbsp;▸&nbsp;&nbsp;'''Adults'''
</font>
</div>
 
<div class="mw-customtoggle-table71" style="cursor: pointer; border-radius: 0 0 5px 5px; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
<font color="#FFF">
&nbsp;&nbsp;▸&nbsp;&nbsp;'''Children'''
</font>
</div>
 
<div style="border-radius: 0 0 0 0; border: solid 1px #20538D; border-bottom: 0px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #A1BCDD; text-align: center;">
<font color="#FFF">
'''Isospora species'''
</font>
</div>
 
<div class="mw-customtoggle-table72" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
<font color="#FFF">
&nbsp;&nbsp;▸&nbsp;&nbsp;'''Adults'''
</font>
</div>
 
<div class="mw-customtoggle-table73" style="cursor: pointer; border-radius: 0 0 5px 5px; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
<font color="#FFF">
&nbsp;&nbsp;▸&nbsp;&nbsp;'''Children'''
</font>
</div>
 
<div style="border-radius: 0 0 0 0; border: solid 1px #20538D; border-bottom: 0px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #A1BCDD; text-align: center;">
<font color="#FFF">
'''Cyclospora species'''
</font>
</div>
 
<div class="mw-customtoggle-table74" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
<font color="#FFF">
&nbsp;&nbsp;▸&nbsp;&nbsp;'''Adults'''
</font>
</font>
</div>
</div>


<div class="mw-customtoggle-table43" style="cursor: pointer; border-radius: 0 0 5px 5px; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
<div class="mw-customtoggle-table75" style="cursor: pointer; border-radius: 0 0 5px 5px; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
<font color="#FFF">
<font color="#FFF">
&nbsp;&nbsp;▸&nbsp;&nbsp;'''Cryptosporidium species'''
&nbsp;&nbsp;▸&nbsp;&nbsp;'''Children'''
</font>
</font>
</div>
</div>


<div class="mw-customtoggle-table43" style="cursor: pointer; border-radius: 0 0 5px 5px; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
<div style="border-radius: 0 0 0 0; border: solid 1px #20538D; border-bottom: 0px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #A1BCDD; text-align: center;">
<font color="#FFF">
<font color="#FFF">
&nbsp;&nbsp;▸&nbsp;&nbsp;'''Isospora species'''
'''Microsporidium species'''
</font>
</font>
</div>
</div>


<div class="mw-customtoggle-table43" style="cursor: pointer; border-radius: 0 0 5px 5px; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
<div class="mw-customtoggle-table76" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
<font color="#FFF">
&nbsp;&nbsp;▸&nbsp;&nbsp;'''Adults'''
</font>
</div>
 
<div class="mw-customtoggle-table77" style="cursor: pointer; border-radius: 0 0 5px 5px; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
<font color="#FFF">
&nbsp;&nbsp;▸&nbsp;&nbsp;'''Children'''
</font>
</div>
<div style="border-radius: 0 0 0 0; border: solid 1px #20538D; border-bottom: 0px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #A1BCDD; text-align: center;">
<font color="#FFF">
<font color="#FFF">
&nbsp;&nbsp;▸&nbsp;&nbsp;'''Cyclospora species'''
 
'''Entamoeba histolytica'''
</font>
</font>
</div>
</div>


<div class="mw-customtoggle-table43" style="cursor: pointer; border-radius: 0 0 5px 5px; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
<div class="mw-customtoggle-table78" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
<font color="#FFF">
<font color="#FFF">
&nbsp;&nbsp;▸&nbsp;&nbsp;'''Microsporidium species'''
&nbsp;&nbsp;▸&nbsp;&nbsp;'''Adults'''
</font>
</font>
</div>
</div>


<div class="mw-customtoggle-table43" style="cursor: pointer; border-radius: 0 0 5px 5px; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
<div class="mw-customtoggle-table79" style="cursor: pointer; border-radius: 0 0 5px 5px; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
<font color="#FFF">
<font color="#FFF">
&nbsp;&nbsp;▸&nbsp;&nbsp;'''Entamoeba histolytica'''
&nbsp;&nbsp;▸&nbsp;&nbsp;'''Children'''
</font>
</font>
</div>
</div>
Line 635: Line 700:
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Trimethoprim-sulfamethoxazole]] 5/25 mg orally q12h X 3 days'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Trimethoprim-sulfamethoxazole]] 5/25 mg orally q12h X 3 days'''''
|-
|-
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompromised patients}}
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompromised patients}}
Line 641: Line 706:
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Trimethoprim-sulfamethoxazole]] 5/25 mg orally q12h X 5-7 days'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Trimethoprim-sulfamethoxazole]] 5/25 mg orally q12h X 5-7 days'''''
|-
|-
|}
|}
Line 653: Line 718:
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen (Only for severe infections or bacteremia)'''''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen (Only for severe infections or bacteremia)'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Doxycycline]] 300 mg orally single dose'''''<BR> OR <BR> ▸ '''''[[Tetracycline]] 500 mg orally q6h X 3 days'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Doxycycline]] 300 mg orally single dose'''''<BR> OR <BR> ▸ '''''[[Tetracycline]] 500 mg orally q6h X 3 days'''''
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen'''''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Trimethoprim-sulfamethoxazole]] 160/800 mg orally q12h X 5-7 days'''''<BR> OR <BR> ▸ '''''[[Ofloxacin]] 300 mg orally q12h X 5-7 days'''''<BR> OR <BR> ▸ '''''[[Norfloxacin]] 400 mg orally q12h X 5-7 days'''''<BR> OR <BR> ▸ '''''[[Ciprofloxacin]] 500 mg orally q12h X 5-7 days'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Trimethoprim-sulfamethoxazole]] 160/800 mg orally q12h X 5-7 days'''''<BR> OR <BR> ▸ '''''[[Ofloxacin]] 300 mg orally q12h X 5-7 days'''''<BR> OR <BR> ▸ '''''[[Norfloxacin]] 400 mg orally q12h X 5-7 days'''''<BR> OR <BR> ▸ '''''[[Ciprofloxacin]] 500 mg orally q12h X 5-7 days'''''
|-
|-
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompromised patients}}
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompromised patients}}
Line 663: Line 728:
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Doxycycline]] 300 mg orally single dose'''''<BR> PLUS <BR> ▸ '''''[[Tetracycline]] 500 mg orally q6h X 3 days'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Doxycycline]] 300 mg orally single dose'''''<BR> PLUS <BR> ▸ '''''[[Tetracycline]] 500 mg orally q6h X 3 days'''''
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen'''''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Trimethoprim-sulfamethoxazole]] 160/800 mg orally q12h X 5-7 days'''''<BR> OR <BR> ▸ '''''[[Ofloxacin]] 300 mg orally q12h X 5-7 days'''''<BR> OR <BR> ▸ '''''[[Norfloxacin]] 400 mg orally q12h X 5-7 days'''''<BR> OR <BR> ▸ '''''[[Ciprofloxacin]] 500 mg orally q12h X 5-7 days'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Trimethoprim-sulfamethoxazole]] 160/800 mg orally q12h X 5-7 days'''''<BR> OR <BR> ▸ '''''[[Ofloxacin]] 300 mg orally q12h X 5-7 days'''''<BR> OR <BR> ▸ '''''[[Norfloxacin]] 400 mg orally q12h X 5-7 days'''''<BR> OR <BR> ▸ '''''[[Ciprofloxacin]] 500 mg orally q12h X 5-7 days'''''
|-
|-
|}
|}
Line 679: Line 744:
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen (Only for severe infections or bacteremia)'''''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen (Only for severe infections or bacteremia)'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Doxycycline]] 300 mg orally single dose'''''<BR> OR <BR> ▸ '''''[[Tetracycline]] 500 mg orally q6h X 3 days'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Doxycycline]] 300 mg orally single dose'''''<BR> OR <BR> ▸ '''''[[Tetracycline]] 500 mg orally q6h X 3 days'''''
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Trimethoprim-sulfamethoxazole]] 5/25 mg orally q12h X 5-7 days'''''
|-
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompromised patients}}
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Doxycycline]] 300 mg orally single dose'''''<BR> PLUS <BR> ▸ '''''[[Tetracycline]] 500 mg orally q6h X 3 days'''''
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Trimethoprim-sulfamethoxazole]] 5/25 mg orally q12h X 5-7 days'''''
|-
|}
|}
 
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table65" style="background: #FFFFFF;"
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompetent patients}}
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Doxycycline]] 300 mg orally single dose'''''<BR> OR <BR> ▸ '''''[[Tetracycline]] 500 mg orally q6h X 3 days'''''
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Trimethoprim-sulfamethoxazole]] 160/800 mg orally q12h X 3 days'''''<BR> OR <BR> ▸ '''''[[Ofloxacin]] 300 mg orally q12h X 3 days'''''<BR> OR <BR> ▸ '''''[[Norfloxacin]] 400 mg orally q12h X 3 days'''''<BR> OR <BR> ▸ '''''[[Ciprofloxacin]] 500 mg orally q12h X 3 days'''''
|-
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompromised patients}}
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Doxycycline]] 300 mg orally single dose'''''<BR> PLUS <BR> ▸ '''''[[Tetracycline]] 500 mg orally q6h X 3 days'''''
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Trimethoprim-sulfamethoxazole]] 160/800 mg orally q12h X 5-7 days'''''<BR> OR <BR> ▸ '''''[[Ofloxacin]] 300 mg orally q12h X 5-7 days'''''<BR> OR <BR> ▸ '''''[[Norfloxacin]] 400 mg orally q12h X 5-7 days'''''<BR> OR <BR> ▸ '''''[[Ciprofloxacin]] 500 mg orally q12h X 5-7 days'''''
|-
|}
|}
 
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table66" style="background: #FFFFFF;"
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompetent patients}}
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Doxycycline]] 300 mg orally single dose'''''<BR> OR <BR> ▸ '''''[[Tetracycline]] 500 mg orally q6h X 3 days'''''
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Trimethoprim-sulfamethoxazole]] 5/25 mg orally q12h X 5-7 days'''''
|-
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompromised patients}}
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Doxycycline]] 300 mg orally single dose'''''<BR> PLUS <BR> ▸ '''''[[Tetracycline]] 500 mg orally q6h X 3 days'''''
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Trimethoprim-sulfamethoxazole]] 5/25 mg orally q12h X 5-7 days'''''
|-
|}
|}
 
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table67" style="background: #FFFFFF;"
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompetent patients}}
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Metronidazole]] 250 mg orally q6h X 10 days'''''<BR> OR <BR> ▸ '''''[[Metronidazole]] 500 mg orally q8h X 10 days'''''
|-
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompromised patients}}
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Doxycycline]] 300 mg orally single dose'''''<BR> PLUS <BR> ▸ '''''[[Tetracycline]] 500 mg orally q6h X 3 days'''''
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Trimethoprim-sulfamethoxazole]] 160/800 mg orally q12h X 5-7 days'''''<BR> OR <BR> ▸ '''''[[Ofloxacin]] 300 mg orally q12h X 5-7 days'''''<BR> OR <BR> ▸ '''''[[Norfloxacin]] 400 mg orally q12h X 5-7 days'''''<BR> OR <BR> ▸ '''''[[Ciprofloxacin]] 500 mg orally q12h X 5-7 days'''''
|-
|}
|}
 
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table68" style="background: #FFFFFF;"
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompetent patients}}
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Metronidazole]] 250 mg orally q6h X 10 days'''''<BR> OR <BR> ▸ '''''[[Metronidazole]] 500 mg orally q8h X 10 days'''''
|-
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompromised patients}}
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Doxycycline]] 300 mg orally single dose'''''<BR> PLUS <BR> ▸ '''''[[Tetracycline]] 500 mg orally q6h X 3 days'''''
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Trimethoprim-sulfamethoxazole]] 5/25 mg orally q12h X 5-7 days'''''
|-
|}
|}
 
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table88" style="background: #FFFFFF;"
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompetent patients}}
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Metronidazole]] 250-750 mg orally q8h X 7-10 days'''''
|-
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompromised patients}}
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Doxycycline]] 300 mg orally single dose'''''<BR> PLUS <BR> ▸ '''''[[Tetracycline]] 500 mg orally q6h X 3 days'''''
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Trimethoprim-sulfamethoxazole]] 160/800 mg orally q12h X 5-7 days'''''<BR> OR <BR> ▸ '''''[[Ofloxacin]] 300 mg orally q12h X 5-7 days'''''<BR> OR <BR> ▸ '''''[[Norfloxacin]] 400 mg orally q12h X 5-7 days'''''<BR> OR <BR> ▸ '''''[[Ciprofloxacin]] 500 mg orally q12h X 5-7 days'''''
|-
|}
|}
 
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table89" style="background: #FFFFFF;"
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompetent patients}}
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Metronidazole]] 250-750 mg orally q8h X 7-10 days'''''
|-
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompromised patients}}
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Doxycycline]] 300 mg orally single dose'''''<BR> PLUS <BR> ▸ '''''[[Tetracycline]] 500 mg orally q6h X 3 days'''''
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen'''''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Trimethoprim-sulfamethoxazole]] 5/25 mg orally q12h X 5-7 days'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Trimethoprim-sulfamethoxazole]] 5/25 mg orally q12h X 5-7 days'''''
|-
|}
|}
 
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table70" style="background: #FFFFFF;"
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompetent patients}}
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen (only if severe)'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Paromomycin]] 500 mg orally q8h X 7 days'''''
|-
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompromised patients}}
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Paromomycin]] 500 mg orally q8h X 14-28 days'''''<BR> THEN <BR> ▸ '''''[[Paromomycin]] 500 mg orally q12h X if needed'''''
|-
|}
|}
 
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table71" style="background: #FFFFFF;"
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompetent patients}}
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen (only if severe)'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Paromomycin]] 500 mg orally q8h X 7 days'''''
|-
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompromised patients}}
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Paromomycin]] 500 mg orally q8h X 14-28 days'''''<BR> THEN <BR> ▸ '''''[[Paromomycin]] 500 mg orally q12h X if needed'''''
|-
|}
|}
 
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table72" style="background: #FFFFFF;"
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompetent patients}}
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Trimethoprim-sulfamethoxazole]] 160/800 mg orally q12h X 7-10 days'''''
|-
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompromised patients}}
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Trimethoprim-sulfamethoxazole]] 160/800 mg orally q6h X 10 days'''''<BR> THEN <BR> ▸ '''''[[Trimethoprim-sulfamethoxazole]] 160/800 mg orally thrice weekly indefinitely'''''
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen (indefinitely for AIDS patients) '''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Sulfadoxine]] 500 mg'''''<BR> PLUS <BR>▸ '''''[[Pyrimethamine]] 25 mg'''''
|-
|}
|}
 
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table73" style="background: #FFFFFF;"
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompetent patients}}
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Trimethoprim-sulfamethoxazole]] 5/25 mg orally q12h X 7-10 days'''''
|-
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompromised patients}}
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Trimethoprim-sulfamethoxazole]] 5/25 mg orally q6h X 10 days'''''<BR> THEN <BR> ▸ '''''[[Trimethoprim-sulfamethoxazole]] 5/25 mg orally thrice weekly indefinitely'''''
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen (indefinitely for AIDS patients) '''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Sulfadoxine]] 500 mg'''''<BR> PLUS <BR>▸ '''''[[Pyrimethamine]] 25 mg'''''
|-
|}
|}
 
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table74" style="background: #FFFFFF;"
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompetent patients}}
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Trimethoprim-sulfamethoxazole]] 160/800 mg orally q12h X 7 days'''''
|-
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompromised patients}}
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Trimethoprim-sulfamethoxazole]] 160/800 mg orally q6h X 10 days'''''<BR> THEN <BR> ▸ '''''[[Trimethoprim-sulfamethoxazole]] 160/800 mg orally thrice weekly indefinitely'''''
|-
|}
|}
 
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table75" style="background: #FFFFFF;"
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompetent patients}}
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Trimethoprim-sulfamethoxazole]] 5/25 mg orally q12h X 7 days'''''
|-
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompromised patients}}
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Trimethoprim-sulfamethoxazole]] 5/25 mg orally q6h X 10 days'''''<BR> THEN <BR> ▸ '''''[[Trimethoprim-sulfamethoxazole]] 5/25 mg orally thrice weekly indefinitely'''''
|-
|}
|}
 
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table76" style="background: #FFFFFF;"
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompetent patients}}
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''Not determined'''''
|-
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompromised patients}}
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Albendazole]] 400 mg orally q12h X 21 days'''''
|-
|}
|}
 
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table77" style="background: #FFFFFF;"
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompetent patients}}
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''Not determined'''''
|-
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompromised patients}}
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Albendazole]] 400 mg orally q12h X 21 days'''''
|-
|}
|}
 
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table78" style="background: #FFFFFF;"
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompetent patients}}
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Metronidazole]] 750 mg orally q8h X 5-10 days'''''<BR> PLUS <BR> ▸ '''''[[Diiodohydroxyquin]] 650 mg orally q8h X 20 days'''''
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Metronidazole]] 750 mg orally q8h X 5-10 days'''''<BR> PLUS <BR> ▸ '''''[[Paromomycin]] 500 mg orally q8h X 7 days'''''
|-
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompromised patients}}
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Metronidazole]] 750 mg orally q8h X 5-10 days'''''<BR> PLUS <BR> ▸ '''''[[Diiodohydroxyquin]] 650 mg orally q8h X 20 days'''''
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Metronidazole]] 750 mg orally q8h X 5-10 days'''''<BR> PLUS <BR> ▸ '''''[[Paromomycin]] 500 mg orally q8h X 7 days'''''
|-
|}
|}
 
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table79" style="background: #FFFFFF;"
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompetent patients}}
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Metronidazole]] 750 mg orally q8h X 5-10 days'''''<BR> PLUS <BR> ▸ '''''[[Diiodohydroxyquin]] 650 mg orally q8h X 20 days'''''
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Metronidazole]] 750 mg orally q8h X 5-10 days'''''<BR> PLUS <BR> ▸ '''''[[Paromomycin]] 500 mg orally q8h X 7 days'''''
|-
|-
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompromised patients}}
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompromised patients}}
Line 689: Line 1,098:
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Doxycycline]] 300 mg orally single dose'''''<BR> PLUS <BR> ▸ '''''[[Tetracycline]] 500 mg orally q6h X 3 days'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Metronidazole]] 750 mg orally q8h X 5-10 days'''''<BR> PLUS <BR> ▸ '''''[[Diiodohydroxyquin]] 650 mg orally q8h X 20 days'''''
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen'''''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Trimethoprim-sulfamethoxazole]] 5/25 mg orally q12h X 5-7 days'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Metronidazole]] 750 mg orally q8h X 5-10 days'''''<BR> PLUS <BR> ▸ '''''[[Paromomycin]] 500 mg orally q8h X 7 days'''''
|-
|-
|}
|}
Line 703: Line 1,112:


[[Category:Emergency medicine]]
[[Category:Emergency medicine]]
[[Category:Infectious disease]]
[[Category:Injuries]]
[[Category:Primary care]]
[[Category:Veterinary medicine]]

Latest revision as of 06:39, 28 July 2020

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Mugilan Poongkunran M.B.B.S [2]

Pathogen Specific

▸ Click on the following categories to expand treatment regimens.[1][2]

Shigella species

  ▸  Adults

  ▸  Children

Non-typhi species of Salmonella

  ▸  Adults

  ▸  Children

Campylobacter species

  ▸  Adults

  ▸  Children

Enterotoxigenic E.coli species

  ▸  Adults

  ▸  Children

Enteropathogenic E.coli species

  ▸  Adults

  ▸  Children

Enteroinvasive E.coli species

  ▸  Adults

  ▸  Children

Enteroaggregative E.coli species

  ▸  Adults

  ▸  Children

Enterohemorrhagic E.coli species

  ▸  Adults

  ▸  Children

Aeromonas / Plesiomonas

  ▸  Adults

  ▸  Children

Yersinia species

  ▸  Adults

  ▸  Children

Vibrio cholerae O1 or O139

  ▸  Adults

  ▸  Children

Toxigenic Clostridium difficile

  ▸  Adults

  ▸  Children

Giardia species

  ▸  Adults

  ▸  Children

Cryptosporidium species

  ▸  Adults

  ▸  Children

Isospora species

  ▸  Adults

  ▸  Children

Cyclospora species

  ▸  Adults

  ▸  Children

Microsporidium species

  ▸  Adults

  ▸  Children

Entamoeba histolytica

  ▸  Adults

  ▸  Children

Immunocompetent patients
Preferred Regimen
Trimethoprim-sulfamethoxazole 160/800 mg orally q12h X 3 days
Alternative Regimen
Ofloxacin 300 mg orally q12h X 3 days
OR
Norfloxacin 400 mg orally q12h X 3 days
OR
Ciprofloxacin 500 mg orally q12h X 3 days
OR
Nalidixic acid 1g orally q24h X 5 days
OR
Ceftriaxone 100 mg/kg/day in 2-3 divided doses X 3 days
OR
Azithromycin X 3 days
Immunocompromised patients
Preferred Regimen
Trimethoprim-sulfamethoxazole 160/800 mg orally q12h X 7-10 days
Alternative Regimen
Ofloxacin 300 mg orally q12h X 7-10 days
OR
Norfloxacin 400 mg orally q12h X 7-10 days
OR
Ciprofloxacin 500 mg orally q12h X 7-10 days
OR
Nalidixic acid 1g orally q24h X 7-10 days
OR
Ceftriaxone 100 mg/kg/day in 2-3 divided doses X 7-10 days
OR
Azithromycin X 7-10 days
Immunocompetent patients
Preferred Regimen
Trimethoprim-sulfamethoxazole 5/25 mg/kg orally q12h X 3 days
Alternative Regimen
Nalidixic acid 55 mg/kg/day X 5 days
OR
Ceftriaxone 100 mg/kg/day in 2-3 divided doses X 3 days
OR
Azithromycin X 3 days
Immunocompromised patients
Preferred Regimen
Trimethoprim-sulfamethoxazole 5/25 mg/kg orally q12h X 7-10 days
Alternative Regimen
Nalidixic acid 55 mg/kg/day X 7-10 days
OR
Ceftriaxone 100 mg/kg/day in 2-3 divided doses X 7-10 days
OR
Azithromycin X 7-10 days
Immunocompetent
Preferred Regimen
Trimethoprim-sulfamethoxazole 160/800 mg orally q12h X 5-7 days
Alternative Regimen
Ofloxacin 300 mg orally q12h X 5-7 days
OR
Norfloxacin 400 mg orally q12h X 5-7 days
OR
Ciprofloxacin 500 mg orally q12h X 5-7 days
OR
Ceftriaxone 100 mg/kg/day in 2-3 divided doses X 5-7 days
Immunocompromised patients
Preferred Regimen
Trimethoprim-sulfamethoxazole 160/800 mg orally q12h X 14 days
Alternative Regimen
Ofloxacin 300 mg orally q12h X 14 days
OR
Norfloxacin 400 mg orally q12h X 14 days
OR
Ciprofloxacin 500 mg orally q12h X 14 days
OR
Ceftriaxone 100 mg/kg/day in 2-3 divided doses X 14 days
Immunocompetent
Preferred Regimen
Trimethoprim-sulfamethoxazole 5/25 mg/kg orally q12h X 5-7 days
Alternative Regimen
Ceftriaxone 100 mg/kg/day in 2-3 divided doses X 5-7 days
Immunocompromised patients
Preferred Regimen
Trimethoprim-sulfamethoxazole 5/25 mg/kg orally q12h X 14 days
Alternative Regimen
Ceftriaxone 100 mg/kg/day in 2-3 divided doses X 14 days
Immunocompetent
Preferred Regimen
Erythromycin 500 mg orally q12h X 5 days
Immunocompromised
Erythromycin 500 mg orally q12h X extended period
Immunocompetent
Preferred Regimen
Erythromycin 500 mg orally q12h X 5 days
Immunocompromised
Erythromycin 500 mg orally q12h X extended period
Immunocompetent patients
Preferred Regimen
Trimethoprim-sulfamethoxazole 160/800 mg orally q12h X 3 days
Alternative Regimen
Ofloxacin 300 mg orally q12h X 3 days
OR
Norfloxacin 400 mg orally q12h X 3 days
OR
Ciprofloxacin 500 mg orally q12h X 3 days
Immunocompromised patients
Preferred Regimen
Trimethoprim-sulfamethoxazole 160/800 mg orally q12h X 5-7 days
Alternative Regimen
Ofloxacin 300 mg orally q12h X 5-7 days
OR
Norfloxacin 400 mg orally q12h X 5-7 days
OR
Ciprofloxacin 500 mg orally q12h X 5-7 days
Immunocompetent patients
Preferred Regimen
Trimethoprim-sulfamethoxazole 5/25 mg orally q12h X 3 days
Immunocompromised patients
Preferred Regimen
Trimethoprim-sulfamethoxazole 5/25 mg orally q12h X 5-7 days
Immunocompetent patients
Preferred Regimen
Erythromycin 500 mg orally q12h X 5 days
Immunocompromised patients
Preferred Regimen
Trimethoprim-sulfamethoxazole 160/800 mg orally q12h X 5-7 days
Alternative Regimen
Ofloxacin 300 mg orally q12h X 5-7 days
OR
Norfloxacin 400 mg orally q12h X 5-7 days
OR
Ciprofloxacin 500 mg orally q12h X 5-7 days
Immunocompetent patients
Preferred Regimen
Erythromycin 500 mg orally q12h X 5 days
Immunocompromised patients
Preferred Regimen
Trimethoprim-sulfamethoxazole 5/25 mg orally q12h X 5-7 days


Immunocompetent patients
Preferred Regimen
Erythromycin 500 mg orally q12h X 5 days
Immunocompromised patients
Preferred Regimen
Trimethoprim-sulfamethoxazole 160/800 mg orally q12h X 5-7 days
Alternative Regimen
Ofloxacin 300 mg orally q12h X 5-7 days
OR
Norfloxacin 400 mg orally q12h X 5-7 days
OR
Ciprofloxacin 500 mg orally q12h X 5-7 days
Immunocompetent patients
Preferred Regimen
Erythromycin 500 mg orally q12h X 5 days
Immunocompromised patients
Preferred Regimen
Trimethoprim-sulfamethoxazole 5/25 mg orally q12h X 5-7 days
Immunocompetent patients
Preferred Regimen
Unknown
Immunocompromised patients
Preferred Regimen (For ETEC)
Ofloxacin 300 mg orally q12h X 5-7 days
OR
Norfloxacin 400 mg orally q12h X 5-7 days
OR
Ciprofloxacin 500 mg orally q12h X 5-7 days
Immunocompetent patients
Preferred Regimen
Unknown
Immunocompromised patients
Preferred Regimen
Unknown
Immunocompetent patients
Preferred Regimen
Role of antibiotics unclear, and administration should be avoided
Immunocompromised patients
Preferred Regimen
Role of antibiotics unclear, and administration should be avoided
Immunocompetent patients
Preferred Regimen
Role of antibiotics unclear, and administration should be avoided
Immunocompromised patients
Preferred Regimen
Role of antibiotics unclear, and administration should be avoided
Immunocompetent patients
Preferred Regimen
Trimethoprim-sulfamethoxazole 160/800 mg orally q12h X 3 days
Alternative Regimen
Ofloxacin 300 mg orally q12h X 3 days
OR
Norfloxacin 400 mg orally q12h X 3 days
OR
Ciprofloxacin 500 mg orally q12h X 3 days
Immunocompromised patients
Preferred Regimen
Trimethoprim-sulfamethoxazole 160/800 mg orally q12h X 5-7 days
Alternative Regimen
Ofloxacin 300 mg orally q12h X 5-7 days
OR
Norfloxacin 400 mg orally q12h X 5-7 days
OR
Ciprofloxacin 500 mg orally q12h X 5-7 days
Immunocompetent patients
Preferred Regimen
Trimethoprim-sulfamethoxazole 5/25 mg orally q12h X 3 days
Immunocompromised patients
Preferred Regimen
Trimethoprim-sulfamethoxazole 5/25 mg orally q12h X 5-7 days
Immunocompetent patients
Preferred Regimen (Only for severe infections or bacteremia)
Doxycycline 300 mg orally single dose
OR
Tetracycline 500 mg orally q6h X 3 days
Alternative Regimen
Trimethoprim-sulfamethoxazole 160/800 mg orally q12h X 5-7 days
OR
Ofloxacin 300 mg orally q12h X 5-7 days
OR
Norfloxacin 400 mg orally q12h X 5-7 days
OR
Ciprofloxacin 500 mg orally q12h X 5-7 days
Immunocompromised patients
Preferred Regimen
Doxycycline 300 mg orally single dose
PLUS
Tetracycline 500 mg orally q6h X 3 days
Alternative Regimen
Trimethoprim-sulfamethoxazole 160/800 mg orally q12h X 5-7 days
OR
Ofloxacin 300 mg orally q12h X 5-7 days
OR
Norfloxacin 400 mg orally q12h X 5-7 days
OR
Ciprofloxacin 500 mg orally q12h X 5-7 days
Immunocompetent patients
Preferred Regimen (Only for severe infections or bacteremia)
Doxycycline 300 mg orally single dose
OR
Tetracycline 500 mg orally q6h X 3 days
Alternative Regimen
Trimethoprim-sulfamethoxazole 5/25 mg orally q12h X 5-7 days
Immunocompromised patients
Preferred Regimen
Doxycycline 300 mg orally single dose
PLUS
Tetracycline 500 mg orally q6h X 3 days
Alternative Regimen
Trimethoprim-sulfamethoxazole 5/25 mg orally q12h X 5-7 days
Immunocompetent patients
Preferred Regimen
Doxycycline 300 mg orally single dose
OR
Tetracycline 500 mg orally q6h X 3 days
Alternative Regimen
Trimethoprim-sulfamethoxazole 160/800 mg orally q12h X 3 days
OR
Ofloxacin 300 mg orally q12h X 3 days
OR
Norfloxacin 400 mg orally q12h X 3 days
OR
Ciprofloxacin 500 mg orally q12h X 3 days
Immunocompromised patients
Preferred Regimen
Doxycycline 300 mg orally single dose
PLUS
Tetracycline 500 mg orally q6h X 3 days
Alternative Regimen
Trimethoprim-sulfamethoxazole 160/800 mg orally q12h X 5-7 days
OR
Ofloxacin 300 mg orally q12h X 5-7 days
OR
Norfloxacin 400 mg orally q12h X 5-7 days
OR
Ciprofloxacin 500 mg orally q12h X 5-7 days
Immunocompetent patients
Preferred Regimen
Doxycycline 300 mg orally single dose
OR
Tetracycline 500 mg orally q6h X 3 days
Alternative Regimen
Trimethoprim-sulfamethoxazole 5/25 mg orally q12h X 5-7 days
Immunocompromised patients
Preferred Regimen
Doxycycline 300 mg orally single dose
PLUS
Tetracycline 500 mg orally q6h X 3 days
Alternative Regimen
Trimethoprim-sulfamethoxazole 5/25 mg orally q12h X 5-7 days
Immunocompetent patients
Preferred Regimen
Metronidazole 250 mg orally q6h X 10 days
OR
Metronidazole 500 mg orally q8h X 10 days
Immunocompromised patients
Preferred Regimen
Doxycycline 300 mg orally single dose
PLUS
Tetracycline 500 mg orally q6h X 3 days
Alternative Regimen
Trimethoprim-sulfamethoxazole 160/800 mg orally q12h X 5-7 days
OR
Ofloxacin 300 mg orally q12h X 5-7 days
OR
Norfloxacin 400 mg orally q12h X 5-7 days
OR
Ciprofloxacin 500 mg orally q12h X 5-7 days
Immunocompetent patients
Preferred Regimen
Metronidazole 250 mg orally q6h X 10 days
OR
Metronidazole 500 mg orally q8h X 10 days
Immunocompromised patients
Preferred Regimen
Doxycycline 300 mg orally single dose
PLUS
Tetracycline 500 mg orally q6h X 3 days
Alternative Regimen
Trimethoprim-sulfamethoxazole 5/25 mg orally q12h X 5-7 days
Immunocompetent patients
Preferred Regimen
Metronidazole 250-750 mg orally q8h X 7-10 days
Immunocompromised patients
Preferred Regimen
Doxycycline 300 mg orally single dose
PLUS
Tetracycline 500 mg orally q6h X 3 days
Alternative Regimen
Trimethoprim-sulfamethoxazole 160/800 mg orally q12h X 5-7 days
OR
Ofloxacin 300 mg orally q12h X 5-7 days
OR
Norfloxacin 400 mg orally q12h X 5-7 days
OR
Ciprofloxacin 500 mg orally q12h X 5-7 days
Immunocompetent patients
Preferred Regimen
Metronidazole 250-750 mg orally q8h X 7-10 days
Immunocompromised patients
Preferred Regimen
Doxycycline 300 mg orally single dose
PLUS
Tetracycline 500 mg orally q6h X 3 days
Alternative Regimen
Trimethoprim-sulfamethoxazole 5/25 mg orally q12h X 5-7 days
Immunocompetent patients
Preferred Regimen (only if severe)
Paromomycin 500 mg orally q8h X 7 days
Immunocompromised patients
Preferred Regimen
Paromomycin 500 mg orally q8h X 14-28 days
THEN
Paromomycin 500 mg orally q12h X if needed
Immunocompetent patients
Preferred Regimen (only if severe)
Paromomycin 500 mg orally q8h X 7 days
Immunocompromised patients
Preferred Regimen
Paromomycin 500 mg orally q8h X 14-28 days
THEN
Paromomycin 500 mg orally q12h X if needed
Immunocompetent patients
Preferred Regimen
Trimethoprim-sulfamethoxazole 160/800 mg orally q12h X 7-10 days
Immunocompromised patients
Preferred Regimen
Trimethoprim-sulfamethoxazole 160/800 mg orally q6h X 10 days
THEN
Trimethoprim-sulfamethoxazole 160/800 mg orally thrice weekly indefinitely
Alternative Regimen (indefinitely for AIDS patients)
Sulfadoxine 500 mg
PLUS
Pyrimethamine 25 mg
Immunocompetent patients
Preferred Regimen
Trimethoprim-sulfamethoxazole 5/25 mg orally q12h X 7-10 days
Immunocompromised patients
Preferred Regimen
Trimethoprim-sulfamethoxazole 5/25 mg orally q6h X 10 days
THEN
Trimethoprim-sulfamethoxazole 5/25 mg orally thrice weekly indefinitely
Alternative Regimen (indefinitely for AIDS patients)
Sulfadoxine 500 mg
PLUS
Pyrimethamine 25 mg
Immunocompetent patients
Preferred Regimen
Trimethoprim-sulfamethoxazole 160/800 mg orally q12h X 7 days
Immunocompromised patients
Preferred Regimen
Trimethoprim-sulfamethoxazole 160/800 mg orally q6h X 10 days
THEN
Trimethoprim-sulfamethoxazole 160/800 mg orally thrice weekly indefinitely
Immunocompetent patients
Preferred Regimen
Trimethoprim-sulfamethoxazole 5/25 mg orally q12h X 7 days
Immunocompromised patients
Preferred Regimen
Trimethoprim-sulfamethoxazole 5/25 mg orally q6h X 10 days
THEN
Trimethoprim-sulfamethoxazole 5/25 mg orally thrice weekly indefinitely
Immunocompetent patients
Preferred Regimen
Not determined
Immunocompromised patients
Preferred Regimen
Albendazole 400 mg orally q12h X 21 days
Immunocompetent patients
Preferred Regimen
Not determined
Immunocompromised patients
Preferred Regimen
Albendazole 400 mg orally q12h X 21 days
Immunocompetent patients
Preferred Regimen
Metronidazole 750 mg orally q8h X 5-10 days
PLUS
Diiodohydroxyquin 650 mg orally q8h X 20 days
Alternative Regimen
Metronidazole 750 mg orally q8h X 5-10 days
PLUS
Paromomycin 500 mg orally q8h X 7 days
Immunocompromised patients
Preferred Regimen
Metronidazole 750 mg orally q8h X 5-10 days
PLUS
Diiodohydroxyquin 650 mg orally q8h X 20 days
Alternative Regimen
Metronidazole 750 mg orally q8h X 5-10 days
PLUS
Paromomycin 500 mg orally q8h X 7 days
Immunocompetent patients
Preferred Regimen
Metronidazole 750 mg orally q8h X 5-10 days
PLUS
Diiodohydroxyquin 650 mg orally q8h X 20 days
Alternative Regimen
Metronidazole 750 mg orally q8h X 5-10 days
PLUS
Paromomycin 500 mg orally q8h X 7 days
Immunocompromised patients
Preferred Regimen
Metronidazole 750 mg orally q8h X 5-10 days
PLUS
Diiodohydroxyquin 650 mg orally q8h X 20 days
Alternative Regimen
Metronidazole 750 mg orally q8h X 5-10 days
PLUS
Paromomycin 500 mg orally q8h X 7 days

References

  1. Guerrant RL, Van Gilder T, Steiner TS, Thielman NM, Slutsker L, Tauxe RV; et al. (2001). "Practice guidelines for the management of infectious diarrhea". Clin Infect Dis. 32 (3): 331–51. doi:10.1086/318514. PMID 11170940.
  2. Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC; et al. (2010). "Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA)". Infect Control Hosp Epidemiol. 31 (5): 431–55. doi:10.1086/651706. PMID 20307191.